证券代码：300318 证券简称：博晖创新 公告编号：临 2025-025 北京博晖创新生物技术集团股份有限公司 关于公司获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"） 近日获得由国家药品监督管理局颁发的《中华人民共和国医疗器械注册证（体外 诊断试剂）》。具体情况如下： 一、医疗器械注册证的具体情况 1、产品名称：轮状病毒、诺如病毒、肠道腺病毒、星状病毒和札如病毒核 酸检测试剂盒（PCR-荧光探针法） 2、注册分类：Ⅲ类 1、医疗器械注册证。 证券代码：300318 证券简称：博晖创新 公告编号：临 2025-025 3、注册证编号：国械注准 20253401042 4、注册证有效期：2025 年 5 月 29 日至 2030 年 5 月 28 日 5、预期用途：本产品用于体外定性检测腹泻患者粪便样本中的轮状病毒（A、 B、C 群）、诺如病毒（GI、GII 型）、肠道腺病毒（40、41 型）、星状病毒和札如 病毒的核酸。 二、对上市公司的影响及风险提示 上述医疗器 ...

Core Viewpoint - The company has received a medical device registration certificate from the National Medical Products Administration for a new in vitro diagnostic reagent, which is expected to enhance its product range and competitive edge in the market [1] Group 1: Product Registration - The product is a nucleic acid testing kit for the detection of rotavirus, norovirus, enteric adenovirus, astrovirus, and sapovirus, using the PCR-fluorescent probe method [1] - The registration classification is Class III, with the registration certificate number being 20253401042, valid from May 29, 2025, to May 28, 2030 [1] Group 2: Market Impact - The acquisition of this registration certificate enriches the company's product offerings, which is beneficial for enhancing its core competitiveness and market expansion capabilities [1] - The new product is significant for the future performance improvement of the company [1]

5月29日，博晖创新今日收盘5.93元，上涨2.07%，最新市净率3.52，总市值48.44亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入2.02亿元，同比-23.05%；净利润-4054437.18 元，同比-120.41%，销售毛利率38.37%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)5博晖创新-330.17523.933.5248.44亿行业平均 49.6447.924.61106.85亿行业中值36.3637.152.4549.28亿1天益医疗-1776.29-3042.591.9022.64亿2澳华内 镜-644.66323.335.1667.94亿3诺唯赞-407.58-482.062.2487.22亿4爱朋医疗-359.62273.204.3329.51亿6奥精 医疗-139.08-203.851.8325.81亿7硕世生物-137.56-2010.081.2340.24亿8睿昂基因-102.37-84.041.4513.25亿9 康泰医学-89.13-75.303.1858.66亿10中红医疗-72.45-57.790.9250.35亿11华大智造-55.85- ...

Group 1 - The core business of Beijing Bohui Innovation Biotechnology Group Co., Ltd. is the research, production, and sales of in vitro diagnostic products, including testing instruments, software, reagents, calibration products, quality control products, and national standard substances [1] - As of the first quarter of 2025, the company reported a revenue of 202 million yuan, a year-on-year decrease of 23.05%, and a net profit of -4.05 million yuan, a year-on-year decrease of 120.41%, with a gross profit margin of 38.37% [1] - The latest closing price of Bohui Innovation was 5.78 yuan, down 2.69%, with a price-to-book ratio of 3.43 and a total market value of 4.722 billion yuan [1] Group 2 - The company has one institutional holder with a total holding of 4.1405 million shares, valued at 2.3 million yuan [1] - The company's PE (TTM) is -321.82, while the industry average PE (TTM) is 48.71, indicating a significant underperformance compared to the industry [2] - The industry median price-to-book ratio is 2.40, while Bohui Innovation's price-to-book ratio is 3.43, suggesting a higher valuation relative to its peers [2]

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-024 北京博晖创新生物技术集团股份有限公司 2024 年度股东大会会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决议案的情况； 2、本次股东大会不涉及变更以往股东大会决议的情形。 一、会议召开和出席情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"）2024 年度股东 大会于 2025 年 5 月 20 日（星期二）下午 14：00 在公司会议室以现场投票和网 络投票相结合的形式召开。通过深圳证券交易所系统进行网络投票的具体时间为： 2025 年 5 月 20 日 9:15—9:25，9:30—11:30 和 13:00—15:00，通过深圳证券交易 所互联网投票系统投票的具体时间为：2025 年 5 月 20 日 9:15 至 15:00 期间的任 意时间。 本次股东大会由公司董事会召集，董事长沈治卫先生主持，公司董事、监事、 高级管理人员及律师等相关人士出席了本次会议。会议的召集、召开与表决程序 符合有关法律、行政法规、部门规章、 ...

北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 电话：010-88004488/66090088 传真：010-66090016 邮编：100005 北京国枫律师事务所 关于北京博晖创新生物技术集团股份有限公司 法律意见书 国枫律股字[2025]A0258号 致：北京博晖创新生物技术集团股份有限公司（贵公司） 北京国枫律师事务所（以下简称"本所"）接受贵公司的委托，指派律师出席并见证 贵公司 2024 年度股东大会（以下简称"本次会议"）。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）、《律师事务所从事证券法律业务管理办法》（以下简称"《证券法律业务管 理办法》"）、《律师事务所证券法律业务执业规则（试行）》（以下简称"《证券法律业务执 业规则》"）等相关法律、行政法规、规章、规范性文件及《北京博晖创新生物技术集团 股份有限公司章程》（以下简称"《公司章程》"）的规定，就本次会议的召集与召开程序、 召集人资格、出席会议人员资格、会议表决程序及表决结果等事宜，出具本法律意见 ...

Company Overview - Beijing Bohui Innovation Biotechnology Group Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic products, including testing instruments, software, reagents, calibration materials, quality control products, and national standard substances [1]. Financial Performance - For Q1 2025, the company reported revenue of 202 million yuan, a year-on-year decrease of 23.05% [1]. - The net profit for the same period was -4,054,437.18 yuan, reflecting a year-on-year decline of 120.41% [1]. - The gross profit margin stood at 38.37% [1]. Market Metrics - As of May 20, the company's stock closed at 5.94 yuan, up 1.54%, with a latest price-to-book ratio of 3.53, marking a 15-day low [1]. - The total market capitalization is 4.852 billion yuan [1]. - Over the past five days, the main capital flow showed a net inflow of 618,100 yuan, although the overall trend was a net outflow of 20.5314 million yuan [1]. Industry Comparison - The company's price-to-earnings (P/E) ratio (TTM) is -330.72, while the industry average is 49.51 [2]. - The company's price-to-earnings (static) ratio is 524.81, compared to the industry average of 47.73 [2]. - The industry median price-to-book ratio is 2.51, while Bohui Innovation's is 3.53 [2].

Financial Performance - In 2024, the company achieved a revenue of 852 million CNY, a year-on-year decline of 18.53% [2] - The net profit attributable to shareholders increased by 137.09% to 92.46 million CNY [2] - Operating costs decreased by 26.58%, sales expenses by 13.58%, and management expenses by 2.50% [1] Business Segments - The bioproducts segment experienced a year-on-year decline of 20.5% [2] - The company plans to focus on blood products, enhancing production capacity and resource integration [2] - The company currently operates 21 plasma collection stations across various regions [3] Future Growth Strategies - The company aims to increase blood product output with the launch of the Yunnan blood product project [4] - The revival of the Langfang rabies vaccine production is expected to contribute to new revenue streams [4] - The introduction of new diagnostic products is anticipated to offset revenue impacts from centralized procurement policies [4] Industry Outlook - The blood products market in China is projected to reach 60 billion CNY in 2024, with a compound annual growth rate (CAGR) of 11.6% expected until 2027 [8] - The in vitro diagnostics market is expected to grow at a CAGR of 5-8% over the next five years [8]

Core Viewpoint - The blood products industry is experiencing a significant divergence in performance among companies, with some reporting growth while others face declines in revenue and profit [1][2]. Group 1: Company Performance in 2024 - Shanghai Laisai (002252) and Tiantan Biological (600161) reported revenue growth of 2.67% and 16.44% respectively, with net profits increasing by 23.25% and 39.58% [1]. - Hualan Biological (002007), Boya Biological (300294), and Bohui Innovation (300318) experienced revenue declines of 18.02%, 34.58%, and 18.53% respectively, while Hualan's net profit fell by 26.57% [1]. - Bohui Innovation managed to turn a profit with a net profit of 0.09 billion yuan, compared to a loss in the previous year [1]. Group 2: Q1 2025 Performance - In Q1 2025, Tiantan Biological, Hualan Biological, and Boya Biological continued to show revenue growth, while Shanghai Laisai, Tiantan Biological, and Paillin Biological saw revenue declines of 2.45%, 0.57%, and 14% respectively [1]. - Hualan Biological's net profit increased by 19.62%, while Shanghai Laisai and Tiantan Biological reported net profit declines of 25.2% and 22.9% respectively [1]. - The decline in profits for Tiantan Biological was attributed to a decrease in product prices that outweighed the benefits of increased sales volume [1]. Group 3: Market Dynamics - The blood products market is expected to maintain stable growth in 2024, with significant competition in the human albumin market due to increased imports [2][3]. - The cancellation of certain medical insurance restrictions is expected to release market demand for coagulation factor products, contributing to their growth [2]. - The overall price trend for blood products is declining, influenced by increased competition and supply exceeding demand for certain products [3]. Group 4: Industry Consolidation - The blood products industry is characterized by high entry barriers, with fewer than 30 companies currently operating due to strict regulations on blood product production [6][7]. - Recent mergers and acquisitions are expected to enhance industry concentration, with leading companies gaining competitive advantages through resource acquisition [6][7]. - Companies like Tiantan Biological and Shanghai Laisai have made significant acquisitions to expand their production capabilities and market presence [7]. Group 5: Market Size and Growth Projections - The blood products market in China reached a scale of 600 billion yuan in 2024, with projections to grow to 780 billion yuan by 2027, reflecting a compound annual growth rate of 11.6% from 2022 to 2027 [8].

证券代码：300318 证券简称：博晖创新 公告编号：临 2025-022 北京博晖创新生物技术集团股份有限公司 第八届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京博晖创新生物技术集团股份有限公司（以下简称"公司"或"博晖创新"）第 八届监事会第十次会议于 2025 年 4 月 28 日在公司会议室召开，会议通知于 2025 年 4月 17日以专人送达、邮件通知或电话通知的方式送达各位监事。会议由公司监事 会主席杜江虹女士主持，会议采取现场和通讯表决相结合方式进行，本次会议应出 席监事 3 人，实际出席监事 3 人。本次会议的召集召开程序符合《公司法》和《公 司章程》的有关规定。 二、监事会会议审议情况 本次会议审议通过了以下议案： 1、审议通过《2025 年第一季度报告》 监事会认为：公司结合 2025 年第一季度的实际经营管理情况编制的《2025 年 第一季度报告》符合《深圳证券交易所创业板股票上市规则》、《上市公司信息披露 管理办法》等法律法规的相关要求。其内容真实、准确、完整的反映了公司 202 ...